OS Therapies' Osteosarcoma Treatment Advances Toward FDA Approval
September 30, 2026 — OS Therapies advances OST-HER2 immunotherapy for osteosarcoma with FDA RMAT designation. Phase 2b results show significant survival improvement. Potential 2026 launch with commercial partner Eversana.